FDA shear flow instrument system

The FDA is seeking a shear flow instrument system designed to replicate in vivo conditions for evaluating human platelets and red blood cells within their physiological environment, as outlined in the solicitation numbered 75F40126Q133903. This acquisition is set aside exclusively for small business concerns under the SBA Total Small Business Set-Aside provision, requiring all offerors to be registered and active in SAM.gov with a valid Unique Entity Identifier at the time of submission. The solicitation references commercial item acquisition procedures and mandates compliance with the offeror representations and certifications clause for commercial products and services. The contract is administered by the FDA Office of Acquisition and Grant Services within the Department of Health and Human Services headquartered in Rockville, Maryland, with Timothy Walbert listed as the primary point of contact. Offers must be submitted by the deadline of June 16, 2026, at 7:00 p.m. Eastern Time, and while the system is intended to advance biomedical research capabilities, specific technical specifications, performance requirements, evaluation criteria, delivery details, and pricing information are not available due to documented system connection errors during data retrieval.